MBRK, VSYM, ARSC, NEXM, SCLD, IMDS OTCPicks.com Stocks to Watch for Wednesday, November 25th
Posted on 11/25/2009 9:16:31 AM in #Stocks | 0 comments comments
Our
Stocks to Watch tomorrow include MiddleBrook Pharmaceuticals Inc. (Nasdaq:
MBRK), View Systems Inc. (OTCBB: VSYM), American Security Resources Corp. (OTC:
ARSC), NexMed Inc. (Nasdaq: NEXM), SteelCloud Inc. (Nasdaq: SCLD) and Imaging
Diagnostic Systems Inc. (OTCBB: IMDS).
MIDDLEBROOK
PHARMACEUTICALS (NASDAQ: MBRK)
"Up
128.57% on Tuesday"
Detailed
Quote: http://www.otcpicks.com/quotes/MBRK.php
MiddleBrook
Pharmaceuticals, Inc. develops and commercializes anti-infective drug products
for the treatment of infectious diseases. It develops a proprietary, once-a-day
pulsatile delivery technology called PULSYS. The company is developing
anti-infective drugs based on its novel biological finding that bacteria
exposed to antibiotics in front- loaded staccato bursts than those under
standard treatment regimens. Its pulsatile product candidates include MOXATAG,
based on the antibiotic amoxicillin, for the treatment of
pharyngitis/tonsillitis (strep throat) for adults and pediatric patients age 12
and older; and Keflex PULSYS product candidate, based on the antibiotic
cephalexin, which is in Phase I clinical trials for skin and skin structure
infections. In addition, MiddleBrook Pharmaceuticals sells its Keflex products
in both capsule and powder formulations for the treatment of skin and skin
structure infections, and upper respiratory tract infections primarily through
pharmaceutical distributors and wholesalers to physicians, hospitals, and
pharmacies in the United States. The company was founded in 1999. It was
formerly known as Advancis Pharmaceutical Corporation and changed its name to
MiddleBrook Pharmaceuticals, Inc. in 2007. MiddleBrook Pharmaceuticals is
headquartered in Germantown,
Maryland.
MBRK
News:
November
5 - MiddleBrook Pharmaceuticals Reports Third Quarter 2009 Results
Solid
3Q Market Share Gains for MOXATAG®; The Height of Strep Throat Season Approaches
Highlights
*
MiddleBrook implemented a $20 maximum co-pay program for MOXATAG. (July 2009)
*
MiddleBrook completed a realignment of its field sales force and reduced its
corporate staff for an estimated $15 million in annualized expense savings.
(Sept. 2009)
*
Approximately 70,000 MOXATAG prescriptions were filled between March 16, 2009,
and Oct. 23, 2009, according to IMS Health National Prescription Audit™ data.
MiddleBrook
Pharmaceuticals, Inc. (Nasdaq: MBRK) announced its financial and operational
results for the quarter ended Sept. 30, 2009.
“MOXATAG
tripled its share of the oral-solid penicillin-class antibiotic market during
the 2009 third quarter,” said MiddleBrook President and CEO John Thievon. “With
the height of the strep throat season approaching in the first calendar quarter
of 2010, we believe our nationwide sales and marketing campaign will continue
to increase awareness of MOXATAG and drive significant market share and
prescription growth over the coming months.”
Third
Quarter 2009 Financial Results
MiddleBrook
reported third quarter 2009 net revenue of $1.1 million, compared to net
revenue of $2.3 million in the third quarter of 2008. Net sales of MOXATAG
(extended-release amoxicillin) Tablets, 775 mg, totaled $(0.6) million for the
2009 third quarter and were negatively impacted by a $1.3 million one-time
cumulative adjustment related to the July 2009 implementation of the MOXATAG
$20 maximum co-pay program. The $1.3 million adjustment applies to MOXATAG
inventory sold into the channel before the third quarter of 2009. Net sales for
the KEFLEX® (cephalexin, USP) franchise totaled $1.7 million in the third
quarter of 2009.
Net
loss was $17.0 million for the 2009 third quarter, compared to a net loss of
$12.5 million attributable to MiddleBrook in the third quarter of 2008. Net
loss per share during the third quarter of 2009 was $0.20, compared to a net
loss per share of $0.19 in the prior-year third quarter.
MiddleBrook
reported cost of goods sold in the amount of $0.5 million for the 2009 third
quarter, compared to $0.3 million in the prior-year period. Research and
development (R&D) expense in the third quarter of 2009 was $1.4 million,
compared to third quarter 2008 R&D expense of $6.9 million. Selling,
general and administrative expense was $16.2 million in the third quarter of
2009, compared to $7.0 million in the prior-year period.
As
of Sept. 30, 2009, MiddleBrook’s cash, cash equivalents, and marketable
securities totaled $28.4 million, compared to $74.7 million as of Dec. 31,
2008.
Outlook
MiddleBrook
is narrowing its 2009 annual revenue guidance and expense estimate and is
providing a total operating expense estimate for 2010. Combined 2009 net sales
for MOXATAG and KEFLEX are now expected to range between $16 and $18 million.
Total 2009 operating expenses are anticipated to range between $75 and $78
million. MiddleBrook estimates that its total 2010 operating expenses will
range between $65 and $70 million. The Company anticipates the need to raise
additional capital to fund operations through 2010.
VIEW
SYSTEMS INCORPORATED (OTCBB: VSYM)
"Up
60.00% on Tuesday"
Detailed
Quote: http://www.otcpicks.com/quotes/VSYM.php
View
Systems, Inc. manufactures and installs weapons detection identification
systems, video management platforms and tele-data communication networks
targeted towards correctional facilities, schools, courthouses, government
agencies, event and sports venues, and commercial businesses.
VSYM
News:
November
24 - View Systems' Product Partner, Belcom, Announces Orders From Saudi Arabia, India,
Bangladesh
and the UAE
View
Systems, Inc. (OTCBB: VSYM), a security and tele-data solutions provider,
announced that the company's leading authorized and exclusive international
dealer and business partner, Belcom, a Belhasa International Company, has received
a second round of orders for ViewScan units and other View Systems products
from Saudi Arabia, Bangladesh, India and the United Arab Emirates. The orders
have been placed by a mixture of government and corporate clientele.
ViewScan
is fast becoming the choice screening system, both domestically and
internationally. It's a computer-based system that can scan up to 1200 people
per hour. As a person passes through the portal, a photograph is taken and
stored on the laptop computer that comes with the unit. Threat objects are
visually located on the computer screen and an audible alert can be set to
sound. The ViewScan produces no harmful emissions so it's safe for everyone.
Belcom
is an authorized and exclusive international dealer and business partner of
View Systems. Belcom represents View Systems' products in the Middle East,
Africa, Saudi Arabia, Kuwait, Qatar,
Bahrain, UAE, Oman, Jordan,
Iraq, India, Pakistan,
Bangladesh and Yemen. Belcom
is a subsidiary of the Belhasa Group of Companies, a trusted security and
services firm with proven performance throughout the Middle East and Africa. Belcom is one of the fastest growing security
services companies in the Middle East today.
Belcom's corporate headquarters is based in Dubai, UAE with field offices located
throughout the MENA region. (Source: www.belcom.ae). Belcom's team has an
impressive track record of successfully completing projects for clients
regardless of location, specifically with ViewScan units currently placed in Saudi Arabia, Bahrain,
UAE, India and Pakistan.
Gautham
Belthur, General Manager of Belcom, states, "There is a phenomenal amount
of interest from various sectors for the ViewScan units. We have been receiving
inquiries from all over the Middle East, Africa and Asia
regions. The most pleasing fact is that not only sensitive government
institutions, but also corporate entities, prefer the ViewScan over traditional
metal detectors for their security needs. The product has received a huge
thumbs-up from all our clients and they are delighted to see top-notch
technology and service from Belcom. Armed with such a positive initial
response, we expect to move quantities of more than 200 units by the end of
2010."
AMERICAN
SECURITY RESOURCES CORPORATION (OTCBB: ARSC)
"Up
50.00% on Tuesday"
Detailed
Quote: http://www.otcpicks.com/quotes/ARSC.php
ARSC
is a holding company actively seeking to acquire companies and technologies
that will advance the development of alternative energies. ARSC, through its
Hydra subsidiary, has developed high volume, mass producible hydrogen fuel
cells. Its American Hydrogen Corp. subsidiary is developing methods to
inexpensively formulate hydrogen.
ARSC
News:
November
24 - Hydra to Receive Three More Patents
The
Buskop Law Group (www.buskoplaw.com) has notified Hydra Fuel Cell Corporation,
a wholly owned subsidiary of American Security Resources Corporation (OTC:
ARSC), that three more of its original patent applications are completely or
partially approved and ready for issue subject to final patent office action.
Buskop
Law Group is patent counsel for American Security Resources Corporation and its
subsidiary, Hydra Fuel Cell Corporation (www.hydrafuelcell.com).
Bob
Farr, President and COO of ARSC, stated, “We are pleased that the US Patent
Office has recognized the unique quality of our original fuel cell development.
Our science has advanced significantly from that time, however, and is far
different from the science in these patents.”
ABOUT
BUSKOP LAW GROUP
Buskop
Law Group is one of Houston’s
leading patent firms. Their services include patent drafting and issuance,
trademark application and issuance, copyright filings, strategic advice on
patent portfolios and foreign patent and trademark filings. Buskop Law Group is
affiliated with a global network of patent and trademark firms in over 20
countries.
NEXMED
INCORPORATED (NASDAQ: NEXM)
"Up
31.63% on Tuesday"
Detailed
Quote: http://www.otcpicks.com/quotes/NEXM.php
NexMed’s
pipeline includes its innovative topical onychomycosis treatment, which is
licensed to Novartis for global development, a late stage alprostadil treatment
for erectile dysfunction, a Phase 2 treatment for female sexual arousal
disorder, and an early stage treatment for psoriasis.
NEXM
News:
November
23 - NexMed, Inc. to Acquire Bio-Quant, Inc.
*
Cash Flow Positive, Growing Business Provides NexMed with Pre-clinical
Capabilities, Added Licensing Expertise and Critical Mass
*
Transaction May Enable Continued NASDAQ Listing
NexMed,
Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® technology,
announced that it has entered into a definitive agreement to acquire Bio-Quant,
Inc., a revenue generating privately-held leading research organization for in
vitro and in vivo contract drug discovery and pre-clinical development
services, headquartered in San Diego, CA. Upon closing of the transaction,
which is expected before the end of the year, Bio-Quant will become a
wholly-owned subsidiary of NexMed. Bassam Damaj, Ph.D., co-founder, current
Chief Executive Officer and Chief Scientific Officer of Bio-Quant, will become
Chief Executive Officer of NexMed, replacing Vivian Liu, who will transition to
the role of Executive Vice President and, in that capacity, Ms. Liu will
continue to be responsible for leading the business development and licensing
efforts for NexMed’s clinical programs. Mark Westgate will remain as NexMed’s
Chief Financial Officer. The Board will be composed of three Bio-Quant nominees
and four NexMed nominees, and Ms. Liu is expected to be appointed as Chairman
of the Board.
The
agreement provides for NexMed’s issuance of 4,000,000 unregistered shares of
its common stock to the Bio-Quant shareholders and a promissory note (the
“Note”) in the amount of approximately $12.1 million due on December 31, 2010.
NexMed can elect to pay all or any portion of the Note by issuing its common
stock. Such repayment in common stock is contingent upon NexMed shareholder
approval. As a condition to closing, there will be a Bio-Quant shareholders
meeting. Certain key shareholders of Bio-Quant have agreed to vote in favor of
the transaction.
Commenting
on today’s news, Ms. Liu stated, “We look forward to welcoming the Bio-Quant
team as a NexMed subsidiary. Through this transaction, NexMed acquires a
revenue generating, cash flow positive business which has grown over 250% in
the past five years and is continuing to grow at present. Moreover, we will
gain preclinical capabilities, add valuable licensing expertise and be able to
leverage Bio-Quant’s existing relationships with key pharmaceutical companies –
all of which will aid in the continued development and the ultimate
commercialization of our products under development.”
Dr.
Damaj, noted, “We are delighted to become part of NexMed, a company with a
novel technology and innovative products which we believe can be better
monetized and generate value for our shareholders. While continuing our normal
course of business as a leading CRO, we will be adding Our established and
growing business, resources, and expertise to NexMed, which should allow NexMed
to continue its business development in a more rapid and efficient manner.”
Mark
Westgate added, “The acquisition of Bio-Quant was an integral part of our
compliance plan presented to the NASDAQ Listing Qualification Panel (the
“Panel”) on Thursday, November 12, 2009. We are hopeful that the signing of
this agreement will give the Panel further confidence that we will regain and
maintain compliance with all applicable continued listing requirements. While
we have yet to receive a decision from the Panel, we are optimistic that the
Panel will continue our listing pending the implementation of our plan.”
FTN
Equity Capital Markets Corp., in New
York City, has served as NexMed’s financial advisor in
the structuring and negotiations of this transaction.
ABOUT
BIO-QUANT
Founded
in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most
experienced CROs for in vitro and in vivo pharmacology services and research
models specializing in oncology, inflammation, immunology, and metabolic
diseases, including diabetes.
STEELCLOUD
INCORPORATED (NASDAQ: SCLD)
"Up
31.91% on Tuesday"
Detailed
Quote: http://www.otcpicks.com/quotes/SCLD.php
SteelCloud
is a developer and manufacturer of compliance based technology solutions. The
Company designs and manufactures specialized servers and appliances for federal
integrators, software vendors and volume users. For both the government and
commercial markets the Company delivers integration services and software
focused on risk management and network management solutions. The Company's ISO
9001:2000 certified Quality Management System provides procedures for
continuous quality improvement in all aspects of its business. Over its 20-year
history, the Company has won numerous awards for technical excellence and
customer satisfaction.
SCLD
News:
November
24 - SteelCloud to Offer a Hosted BlackBerry Enterprise Server Solution Including License
Administration to International Hosting Service Providers
SteelCloud,
Inc. (Nasdaq: SCLD), a leading developer of mobility computing appliance
solutions announced that it has signed a new agreement with Research In Motion
("RIM"), enabling it to offer a complete Hosted BlackBerry Enterprise
Server solution that includes license administration to hosting service
providers around the world. These licenses will enable hosting service
providers to offer a hosted BlackBerry service to their customers.
The
Company believes that it will begin to recognize revenue from hosting service
providers under this agreement in the current quarter.
Additionally,
SteelCloud, as a BlackBerry® Alliance Elite Member, is a sponsor at the
BlackBerry EMEA Alliance Summit 2009 being held in Rome on November 25th-27th. This summit is a
gathering of BlackBerry Alliance Program members from Europe, Africa, and the Middle East.
"SteelCloud
has been working over the last six months to ensure that we will provide the
international hosting service provider community with the very best service and
license administration for their BlackBerry Enterprise Server software,"
said Brian Hajost, SteelCloud's President and CEO. "We have received
enthusiastic interest from hosting service providers around the world and look
forward to offering them both licensing support and the SteelWorks appliance as
an attractive vehicle for them to migrate to the new BlackBerry® Enterprise
Server v5.0."
IMAGING
DIAGNOSTIC SYSTEMS (OTCBB: IMDS)
"Up
32.13% on Tuesday"
Detailed
Quote: http://www.otcpicks.com/quotes/IMDS.php
Imaging
Diagnostic Systems, Inc. has developed a revolutionary new imaging device to
aid in the detection and management of breast cancer. The CTLM® system is a
breast imaging system that utilizes patented continuous wave laser technology
and computer algorithms to create 3-D images of the breast. The procedure is
non-invasive, painless, and does not expose the patient to ionizing radiation
or painful breast compression. CT Laser Mammography (CTLM®) is designed to be
used in conjunction with mammography. It reveals information about blood distribution
in the breast and may visualize the process of angiogenesis, which usually
accompanies tumor growth. The Company is currently engaged in collecting
clinical data to support the Premarket approval application for marketing
clearance in the U.S.
The FDA has determined that the Company’s clinical study is a non-significant
risk (NSR) investigational device study under 812.3(m) of the investigational
device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by
United States Federal Law to investigational use only in the United States.
IMDS
News:
October
14 - Emerging Stock Report Initiates Independent Research Coverage On Imaging
Diagnostic Systems, Inc.
Emerging
Stock Report, a leading provider of sector specific independent investment
research, has initiated coverage on Imaging Diagnostic Systems, Inc. (OTCBB:
IMDS). Emerging Stock Report is currently offering a complimentary trial
subscription. To view its research go to www.emergingstockreport.com.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper,
TX 75078,
Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This
email address is being protected from spam bots, you need Javascript enabled to
view it.
DO
NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We
are not registered as a securities broker-dealer or an investment adviser
either with the U.S. Securities and Exchange Commission (the "SEC")
or with any state securities regulatory authority. We are neither licensed nor
qualified to provide investment advice. OTCPicks.com makes no recommendation
that the purchase of securities of companies profiled in this web site is
suitable or advisable for any person or that an investment such securities will
be profitable. In general, given the nature of the companies profiled and the
lack of an active trading market for their securities, investing in such
securities is highly speculative and carries a high degree of risk. You are
receiving this email because you have registered on OTCPicks.com or one of our
affiliate companies.
The
information contained in our report should be viewed as commercial
advertisement and is not intended to be investment advice. The report is not
provided to any particular individual with a view toward their individual
circumstances. The information contained in our report is not an offer to buy
or sell securities. We distribute opinions, comments and information free of
charge exclusively to individuals who wish to receive them.
Our
newsletter and website have been prepared for informational purposes only and
are not intended to be used as a complete source of information on any
particular company. An individual should never invest in the securities of any
company profiled based solely on information contained in our reports.
Individuals should assume that all information contained in the report about
profiled companies is not trustworthy unless verified by their own independent
research.
Any
individual who chooses to invest in any securities should do so with caution.
Investing in securities is speculative and carries a high degree of risk; you
may lose some or all of the money that is invested. Always research your own
investments and consult with a registered investment advisor or licensed
stockbroker before investing.
Information
contained in our report will contain "forward looking statements" as
defined under Section 27A of the Securities Act of 1933 and Section 21B of the
Securities Exchange Act of 1934. Subscribers are cautioned not to place undue
reliance upon these forward-looking statements. These forward-looking
statements are subject to a number of known and unknown risks and uncertainties
outside of our control that could cause actual operations or results to differ
materially from those anticipated. Factors that could affect performance
include, but are not limited to, those factors that are discussed in each
profiled company's most recent reports or registration statements filed with
the SEC. You should consider these factors in evaluating the forward-looking
statements included in the report and not place undue reliance upon such
statements. We are committed to providing factual information on the companies
that are profiled. However, we do not provide any assurance as to the accuracy
or completeness of the information provided, including information regarding a
profiled company's plans or ability to effect any planned or proposed actions.
We have no first-hand knowledge of any profiled company's operations and
therefore cannot comment on their capabilities, intent, resources, nor
experience and we make no attempt to do so. Statistical information, dollar
amounts, and market size data was provided by the subject company and related
public information sources which we believe to be reliable but we cannot
guarantee the accuracy of the information. To the fullest extent of the law, we
will not be liable to any person or entity for the quality, accuracy,
completeness, reliability, or timeliness of the information provided in the
report, or for any direct, indirect, consequential, incidental, special or
punitive damages that may arise out of the use of information we provide to any
person or entity (including, but not limited to, lost profits, loss of
opportunities, trading losses, and damages that may result from any inaccuracy
or incompleteness of this information). We encourage you to invest carefully
and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure:
OTCPicks.com has not been compensated by any of the companies covered in this
release.
|